Trial
NCT01620216
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
OHSU Knight Cancer Institute
Collaborators
National Cancer Institute (NCI); Oregon Health and Science University
Condition
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Intervention
Antitumor Drug Screening Assay
Why stopped
Unable to recruit enough eligible subjects
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-04